Indivior deserves a closer look. The pharmaceutical company, ticker INDV, is maintaining its appeal after strong FY25 earnings. While INDV showed no movement at $28.97 today, its recent performance and future plans warrant investor attention.
Indivior has experienced a rally of over 300% since its 2024 lows, fueled by Sublocade market share stability, effective cost controls, and shareholder activism. Management is targeting 8% sales growth for Sublocade in 2026, demonstrating confidence in their core product. Furthermore, INDV aims for a 48% adjusted EBITDA margin, highlighting a commitment to profitability.
What truly sets Indivior apart is its attractive valuation, currently below 10x NTM EV/EBITDA, coupled with an impressive 10% free cash flow yield. This financial strength supports a recently approved $400 million share buyback program for 2026-2027, a clear signal of management's belief in the company's intrinsic value and a commitment to return capital to shareholders. This buyback should provide a floor for the stock and boost investor confidence.
While the broader market saw the SPY decline -1.71% and the IWM drop -1.75%, INDV's resilience underscores its unique position and potential for continued growth. The approved buyback program and targeted sales growth indicate a positive outlook for the company.